Seletracetam enhances short term depression in vitro

Epilepsy Research

Volumn 117, Issue , 2015, Pages 17-22

  Yang, Xiaofeng ^a,c   Meehan, Anna L ^a   Rothman, Steven M ^a,b   Dubinsky, Janet M ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b Mercy Clinic Child Neurology   (United States)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Anticonvulsants; Antiepileptic drugs; Epilepsy; Levetiracetam; Seletracetam; SV2A; Synaptic vesicles

Indexed keywords

ETIRACETAM; MEMBRANE PROTEIN; SELETRACETAM; SYNAPTIC VESICLE PROTEIN 2A; UNCLASSIFIED DRUG; 2 PYRROLIDONE DERIVATIVE; ANTICONVULSIVE AGENT;

ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG PROTEIN BINDING; DRUG TRANSPORT; EXCITATORY POSTSYNAPTIC POTENTIAL; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL SLICE; IN VITRO STUDY; INCUBATION TIME; NERVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; RAT; SCHAFFER COLLATERAL PATHWAY; SHORT TERM DEPRESSION; STIMULUS RESPONSE; SYNAPSE VESICLE; SYNAPTIC POTENTIAL; SYNAPTIC TRANSMISSION; ANIMAL; DRUG EFFECTS; NERVE CELL PLASTICITY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTICONVULSANTS; CA1 REGION, HIPPOCAMPAL; EXCITATORY POSTSYNAPTIC POTENTIALS; NEURONAL PLASTICITY; PYRROLIDINONES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84946218209     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2015.08.006     Document Type: Article

References (32)

1. Bercsenyi K., Giribaldi F., Schiavo G. The elusive compass of clostridial neurotoxins: deciding when and where to go?. Curr. Top. Microbiol. Immunol. 2013, 364:91-113.
2. Crowder K.M., Gunther J.M., Jones T.A., Hale B.D., Zhang H.Z., Peterson M.R., Scheller R.H., Chavkin C., Bajjalieh S.M. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc. Natl. Acad. Sci. U.S.A. 1999, 96:15268-15273.
3. Custer K.L., Austin N.S., Sullivan J.M., Bajjalieh S.M. Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J. Neurosci. 2006, 26:1303-1313.
4. Dionisio S., Brown H., Boyle R., Blum S. Managing the generalised tonic-clonic seizure and preventing progress to status epilepticus: a stepwise approach. Intern. Med. J. 2013, 43:739-746.
5. Frycia A., Starck J.P., Jadot S., Lallemand B., Leclercq K., Lo Brutto P., Matagne A., Verbois V., Mercier J., Kenda B. Discovery of indolone acetamides as novel SV2A ligands with improved potency toward seizure suppression. ChemMedChem 2010, 5:200-205.
6. Gillard M., Fuks B., Leclercq K., Matagne A. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur. J. Pharmacol. 2011, 664:36-44.
7. Glauser T., Ben-Menachem E., Bourgeois B., Cnaan A., Guerreiro C., Kalviainen R., Mattson R., French J.A., Perucca E., Tomson T. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013, 54:551-563.
8. 2+ regulators in neurotransmitter release. Neuron 1999, 24:1003-1016.
9. Kaminski R.M., Matagne A., Patsalos P.N., Klitgaard H. Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam. Epilepsia 2009, 50:387-397.
10. Kay A.R., Alfonso A., Alford S., Cline H.T., Holgado A.M., Sakmann B., Snitsarev V.A., Stricker T.P., Takahashi M., Wu L.G. Imaging synaptic activity in intact brain and slices with FM1-43 in C. elegans, lamprey, and rat. Neuron 1999, 24:809-817.
11. Klitgaard H., Matagne A., Gobert J., Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol. 1998, 353:191-206.
12. Klitgaard H., Matagne A., Grimee R., Vanneste-Goemaere J., Margineanu D.G. Electrophysiological, neurochemical and regional effects of levetiracetam in the rat pilocarpine model of temporal lobe epilepsy. Seizure 2003, 12:92-100.
13. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:9861-9866.
14. 2+ increase in rat cortical neurons in vitro. Epilepsia 2009, 50:702-710.
15. Matagne A., Klitgaard H. Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man. Epilepsy Res. 1998, 31:59-71.
16. Matagne A., Klitgaard H. Levetiracetam protects against seizures in fully hippocampal kindled rats. Epilepsia 1999, 40(Suppl. 7):137.
17. Matagne A., Margineanu D.G., Potschka H., Loscher W., Michel P., Kenda B., Klitgaard H. Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy. Eur. J. Pharmacol. 2009, 614:30-37.
18. Meehan A.L., Yang X., McAdams B.D., Yuan L., Rothman S.M. A new mechanism for antiepileptic drug action: vesicular entry may mediate the effects of levetiracetam. J. Neurophysiol. 2011, 106:1227-1239.
19. Meehan A.L., Yang X.F., Yuan L.L., Rothman S.M. Levetiracetam has an activity-dependent effect on inhibitory transmission. Epilepsia 2012, 53:469-476.
20. Nowack A., Malarkey E.B., Yao J., Bleckert A., Hill J., Bajjalieh S.M. Levetiracetam reverses synaptic deficits produced by overexpression of SV2A. PLoS ONE 2011, 6:e29560.
21. Rigo J.M., Hans G., Nguyen L., Rocher V., Belachew S., Malgrange B., Leprince P., Moonen G., Selak I., Matagne A., Klitgaard H. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal. Br. J. Pharmacol. 2002, 136:659-672.
22. Rigo J.M., Nguyen L., Hans G., Belachew S., Moonen G., Matagne A., Klitgaard H. Seletracetam (ucb 44212): effect on inhibitory and excitatory neurotransmission. Epilepsia 2005, 46(Suppl. 8):110.
23. 2+ channels through an intracellular pathway. Mol. Pharmacol. 2012, 82:199-208.
24. Wan Q.F., Zhou Z.Y., Thakur P., Vila A., Sherry D.M., Janz R., Heidelberger R. SV2 acts via presynaptic calcium to regulate neurotransmitter release. Neuron 2010, 66:884-895.
25. Wright C., Downing J., Mungall D., Khan O., Williams A., Fonkem E., Garrett D., Aceves J., Kirmani B. Clinical pharmacology and pharmacokinetics of levetiracetam. Front. Neurol. 2013, 4:192.
26. Yang X.F., Ouyang Y., Kennedy B.R., Rothman S.M. Cooling blocks rat hippocampal neurotransmission by a presynaptic mechanism: observations using 2-photon microscopy. J. Physiol. 2005, 567:215-224.
27. Yang X.F., Rothman S.M. Levetiracetam has a time- and stimulation-dependent effect on synaptic transmission. Seizure 2009, 18:615-619.
28. Yang X.F., Weisenfeld A., Rothman S.M. Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission. Epilepsia 2007, 48:1861-1869.
29. Yao J., Bajjalieh S.M. Synaptic vesicle protein 2 binds adenine nucleotides. J. Biol. Chem. 2008, 283:20628-20634.
30. Yao J., Nowack A., Kensel-Hammes P., Gardner R.G., Bajjalieh S.M. Cotrafficking of SV2 and synaptotagmin at the synapse. J. Neurosci. 2010, 30:5569-5578.
31. Zhang Q., Li Y., Tsien R.W. The dynamic control of kiss-and-run and vesicular reuse probed with single nanoparticles. Science 2009, 323:1448-1453.
32. 2+ currents. Seizure 2001, 10:279-286.